Effect of vitamin C on parathyroid hormone in hemodialysis patients with mild to moderate secondary hyperparathyroidism

Iranian Journal of Kidney Diseases

Volumn 5, Issue 6, 2011, Pages 410-415

  Sanadgol, Houshang ^a   Bayani, Mahtab ^a   Mohammadi, Mahdi ^b   Bayani, Baktash ^c   Mashhadi, Mohammad Ali ^a  

^a ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ZAHEDAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Ascorbic acid; Hemodialysis; Parathyroid hormone; Secondary hyperparathyroidism

Indexed keywords

ASCORBIC ACID; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; VITAMIN D;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG EFFECT; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERPARATHYROIDISM; KIDNEY FAILURE; MALE; PARATHYROID HORMONE BLOOD LEVEL;

ADULT; ASCORBIC ACID; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INJECTIONS, INTRAVENOUS; KIDNEY FAILURE, CHRONIC; MALE; PARATHYROID HORMONE; RENAL DIALYSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME; VITAMINS;

EID: 80755129417     PISSN: 17358582     EISSN: 17358604     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. US Renal Data System. USRDS 1999 Annual data reports. U.S. Department of Health and Human Services. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease; 1999.
2. Gambaro G, D'Angelo A, Conte M, Bonfante L, De Biase V, Lupo A. Silent chronic kidney disease epidemic seen from Europe: designing strategies for clinical management of the early stages. J Nephrol. 2005;18:123-35.
3. Coresh J, Byrd-Holt D, Astor BC, et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol. 2005;16:180-8.
4. Mahdavi-Mazdeh M. Why do we need chronic kidney disease screening and which way to go? Iran J Kidney Dis. 2010;4:275-81.
5. Polzin DJ, Osborne CA, Jacob F, Ross S. Chronic renal failure. In: Ettinger SJ, Feldman EC, editors. Textbook of veterinary internal medicine. 5th ed. Philadelphia: WB Saunders; 2000. p. 1634-62.
6. Massry SG. Is parathyroid hormone a uremic toxin? Nephron. 1977;19:125-30.
7. Massry SG. Pathogenesis of the anemia of uremia: role of secondary hyperparathyroidism. Kidney Int Suppl. 1983;16:S204-7.
8. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis. 1998;31:607-17.
9. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis. 2000;35:1226-37.
10. US Renal Data System. USRDS 2002 Annual data reports. U.S. Department of Health and Human Services. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease; 1999.
11. Weiner DE, Tighiouart H, Vlagopoulos PT, et al. Effects of anemia and left ventricular hypertrophy on cardiovascular disease in patients with chronic kidney disease. J Am Soc Nephrol. 2005;16:1803-10.
12. Assadi F. Hypercalcemia: an evidence-based approach to clinical cases. Iran J Kidney Dis. 2009;3:71-9.
13. Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999;99:2434-9.
14. Davies MR, Hruska KA. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int. 2001;60:472-9.
15. Akizawa T, Suzuki M, Akiba T, Nishizawa Y, Kurokawa K. Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients. Am J Kidney Dis. 2001;38:S147-51.
16. Akizawa T, Ohashi Y, Akiba T, et al. Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism. Ther Apher Dial. 2004;8:480-91.
17. Mahdavi-Mazdeh M, Zamyadi M, Norouzi S, Heidary Rouchi A. Management of calcium and phosphorus metabolism in hemodialysis patients in Tehran Province, Iran. Iran J Kidney Dis. 2007;1:25-8.
18. Richter A, Kuhlmann MK, Seibert E, Kotanko P, Levin NW, Handelman GJ. Vitamin C deficiency and secondary hyperparathyroidism in chronic haemodialysis patients. Nephrol Dial Transplant. 2008;23:2058-63.
19. Deicher R, Ziai F, Bieglmayer C, Schillinger M, Horl WH. Low total vitamin C plasma level is a risk factor for cardiovascular morbidity and mortality in hemodialysis patients. J Am Soc Nephrol. 2005;16:1811-8.
20. Bohm V, Tiroke K, Schneider S, Sperschneider H, Stein G, Bitsch R. Vitamin C status of patients with chronic renal failure, dialysis patients and patients after renal transplantation. Int J Vitam Nutr Res. 1997;67:262-6.
21. Jackson P, Loughrey CM, Lightbody JH, McNamee PT, Young IS. Effect of hemodialysis on total antioxidant capacity and serum antioxidants in patients with chronic renal failure. Clin Chem. 1995;41:1135-8.
22. Levine M, Rumsey SC, Daruwala R, Park JB, Wang Y. Criteria and recommendations for vitamin C intake. JAMA. 1999;281:1415-23.
23. Singh AK. Vitamin C in the management of erythropoietin resistant anemia in chronic kidney disease [cited 12 April, 2011]. Medscape Education [home page on the internet]. Available from: http://www.medscape.org/viewarticle/551577
24. Handelman GJ. Vitamin C deficiency in dialysis patients- -are we perceiving the tip of an iceberg? Nephrol Dial Transplant. 2007;22:328-31.
25. Makar SH, Sawires HK, Farid TM, Ali WM, Schaalan M. Effect of high-flux versus low-flux dialysis membranes on parathyroid hormone. Iran J Kidney Dis. 2010;4:327-32.
26. Attallah N, Osman-Malik Y, Frinak S, Besarab A. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia. Am J Kidney Dis. 2006;47:644-54.
27. Giancaspro V, Nuzziello M, Pallotta G, Sacchetti A, Petrarulo F. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial. J Nephrol. 2000;13:444-9.
28. McCarron DA, Lenfesty B, Narasimhan N, Barry JM, Vetto RM, Bennett WM. Anatomical heterogeneity of parathyroid glands in posttransplant hyperparathyroidism. Am J Nephrol. 1988;8:388-91.
29. Arnold A, Brown MF, Urena P, Gaz RD, Sarfati E, Drueke TB. Monoclonality of parathyroid tumors in chronic renal failure and in primary parathyroid hyperplasia. J Clin Invest. 1995;95:2047-53.
30. Akizawa T, Shiizaki K, Hatamura I, et al. New strategies for the treatment of secondary hyperparathyroidism. Am J Kidney Dis. 2003;41:S100-3.
31. Drueke TB. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int. 1995;48:259-72.
32. Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis. 1994;23:229-36.
33. Sanchez CP, Goodman WG, Salusky IB. Prevention of renal osteodystrophy in predialysis patients. Am J Med Sci. 1999;317:398-404.
34. Martin KJ, Gonzalez EA. Strategies to minimize bone disease in renal failure. Am J Kidney Dis. 2001;38:1430-6.
35. Goodman WG, Goldin J, Kuizon BD, et al. Coronary- artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478-83.
36. Young EW, Albert JM, Satayathum S, et al. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int. 2005;67:1179-87.
37. Salusky IB, Goodman WG. Cardiovascular calcification in end-stage renal disease. Nephrol Dial Transplant. 2002;17:336-9.
38. Deicher R, Horl WH. Vitamin C in chronic kidney disease and hemodialysis patients. Kidney Blood Press Res. 2003;26:100-6.
39. Gey KF. Vitamins E plus C and interacting conutrients required for optimal health. A critical and constructive review of epidemiology and supplementation data regarding cardiovascular disease and cancer. Biofactors. 1998;7:113-74.
40. Nguyen AT, Lethias C, Zingraff J, Herbelin A, Naret C, Descamps-Latscha B. Hemodialysis membrane-induced activation of phagocyte oxidative metabolism detected in vivo and in vitro within microamounts of whole blood. Kidney Int. 1985;28:158-67.
41. Peuchant E, Carbonneau MA, Dubourg L, et al. Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: vitamins A, E, and iron status. Free Radic Biol Med. 1994;16:339-46.
42. Alkhunaizi AM, Chan L. Secondary oxalosis: a cause of delayed recovery of renal function in the setting of acute renal failure. J Am Soc Nephrol. 1996;7:2320-6.
43. Pru C, Eaton J, Kjellstrand C. Vitamin C intoxication and hyperoxalemia in chronic hemodialysis patients. Nephron. 1985;39:112-6.
44. Costello JF, Sadovnic MJ, Cottington EM. Plasma oxalate levels rise in hemodialysis patients despite increased oxalate removal. J Am Soc Nephrol. 1991;1:1289-98.
45. McCauley LK, Koh AJ, Beecher CA, Cui Y, Rosol TJ, Franceschi RT. PTH/PTHrP receptor is temporally regulated during osteoblast differentiation and is associated with collagen synthesis. J Cell Biochem. 1996;61:638-47.
46. Friedman PA, Coutermarsh BA, Kennedy SM, Gesek FA. Parathyroid hormone stimulation of calcium transport is mediated by dual signaling mechanisms involving protein kinase A and protein kinase C. Endocrinology. 1996;137:13-20.